Quadrant Healthcare
Article Abstract:
Quadrant Healthcare should benefit from the settlement of a dispute relating to ownership of a patent, and the dismissal of the founder, Bruce Roser, as chief operating officer. The company will then be able to sign licensing agreements with big drugs companies which have shown interest in Quadrant's core technology. The company could lose its court case but this would only involve losing one patent and paying 3 million pound sterling in damages to Roser.
Publication Name: Investors Chronicle
Subject: Business
ISSN: 0261-3115
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
On track to sustained growth
Article Abstract:
Bangladesh's Square Pharmaceuticals built its reputatiproviding access to advanced technological manufacturing. The firm's market share grew 11% between 1982 and 1996, from 4% to 15%, and offers more than 70 products. A new plant that would double current production capacity is scheduled for construction in 1998.
Publication Name: Asiamoney
Subject: Business
ISSN: 1607-0526
Year: 1997
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Thumbs up for Glaxo. Phytopharm: Chinese checkers
- Abstracts: Speculating on biotechs. Quadrant Healthcare: Still attractive. The last privatisation
- Abstracts: Picking the best of the promise keepers. Pooling resources to beat the market
- Abstracts: Heart stopping. Shield's big deal. Sum of the parts worth more than the whole
- Abstracts: The operation and interaction of the child tax credit with other personal credits. Individual income tax planning with a FLP/LLC